Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials.
about
Clustered precursors in bone marrow sections predict early relapse in patients with acute myeloid leukemia within hematologic remissionPediatric AML: From Biology to Clinical ManagementChildhood acute myeloid leukaemiaPhase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a paediatric oncology group study.Capillary nano-immunoassay for Akt 1/2/3 and 4EBP1 phosphorylation in acute myeloid leukemia.Gene expression profiles associated with pediatric relapsed AML.The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.Development of treatment and clinical results in childhood acute myeloid leukemia in Poland.Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia.Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.A critical review of which children with acute myeloid leukaemia need stem cell procedures.How I treat paediatric relapsed acute myeloid leukaemia.Childhood acute myeloid leukemia: an Indian perspective.Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia.Outcome of refractory and relapsed acute myeloid leukemia in children treated during 2005-2011 - experience of the Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG).Variations in non-pharmacological anti-infective measures in childhood leukemia--results of an international survey.High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology CenterUpdate on optimal management of acute myeloid leukemiaDisulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing.Access to allogeneic hematopoietic SCT for patients with MDS or relapsed AML treated according to protocols of the Dutch Childhood Oncology Group.Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.Checkpoint inhibition in pediatric hematologic malignancies.Salvaged allogeneic hematopoietic stem cell transplantation for pediatric chemotherapy refractory acute leukemia.A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium.Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.Acute myeloid leukemia in children: Current status and future directions.Allo-SCT using BU, CY and melphalan for children with AML in second CR.Treatment of children with acute myeloid leukaemia who relapsed after allogeneic haematopoietic stem cell transplantation.Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse.Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.
P2860
Q21245489-EE18ECF1-55E0-4081-9191-9CA387744689Q26799773-E1EA45AA-1C7E-4FA9-881C-1C303A69BA11Q27005960-BD26470F-C034-45AC-8819-D120D8C17B55Q33400806-05A15399-07C1-49FA-8CCF-A9E38CE55009Q33841929-00F5EC1A-DC78-4713-95A0-5333C18FE648Q35302035-E8E625E7-3469-4755-935F-41E044600E8CQ35643005-8C55C868-DFE7-470E-BED4-13B30DD49183Q36036315-496D2858-BEB5-4710-B1CF-68E469B8254EQ36053792-102F4382-BD35-46E4-92BF-DD79C95E4464Q36107961-A4163A0C-905C-4630-B21E-38E7C2099000Q36736376-64FD512D-21D6-4455-8CF9-C47CFA7C8FE6Q37501821-23919F91-A8EE-430B-A832-6A0263442670Q37734163-6589D8EE-EBBF-4EE5-B9F9-AA1C1D262759Q38066860-523AD08A-7DA8-4F68-95BC-EC6FC5BF4413Q38097334-B5B6FEA6-F12E-4DE0-8C5F-65264D44626CQ38112088-791B0425-6A77-4CDC-9A17-D922A6262813Q38155455-7532E771-21D9-4F5F-BDA3-8B62245CF3E3Q38205864-87A52CF2-4488-4401-A564-27B7D398403AQ38212509-AFAD5159-4E6F-43D8-862A-6B70355BEFFDQ38425422-E3C5AF83-2659-4D77-912C-6361C9889CF4Q38821563-5C783521-D2AD-4ACA-8C39-187768DD010CQ39184229-C1F708CC-1E5F-4B3A-BCB5-7C197AA2031CQ39640669-96B760DE-E6BD-43F0-B081-0A96A7DAADEFQ41478883-1613F78E-2DD0-4178-B853-15BFE692F8AEQ41864778-6F598E3E-3D5F-4887-8204-5E4EC5DA8025Q41894404-849949AA-F399-489E-B59F-72D865678B9DQ42176458-D4E696D9-8A4C-4741-89F2-5877953727AEQ42322251-F93E630A-698D-4419-8925-CE672D9A7463Q43856934-FAA62FA2-9504-41C6-9F47-6CAA4C7E6FFCQ44646134-CABD91F4-99CA-4F51-A662-DBBAF6634C7DQ45944767-94E83243-897D-4E9E-AC10-20CBF38D3487Q48505253-71E3A056-A00A-4D6A-8D19-E9895423A2CAQ50020673-58622CB5-03CE-461A-81D7-E351A7A3C8F2Q52760255-B4DF03FF-0351-474F-98FA-80C01ED7D0F6Q52897332-85797F69-55A1-4504-A662-CDBEDA7A9FDDQ53108503-2F5DAC13-930E-465D-9692-4C208F7D2E2DQ53136977-CC96908C-C2FD-4148-B6E7-8116C682FBC6Q54207519-10ACC234-B287-4464-9111-82F1E98E0840Q54342441-092A4B9A-EE0B-4848-B5C0-8D3C049C7BB8Q54342479-BDEE7DF3-4440-44E0-9721-1B6AB7B26311
P2860
Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Consequent and intensified rel ...... ee consecutive AML-BFM trials.
@en
Consequent and intensified rel ...... ee consecutive AML-BFM trials.
@nl
type
label
Consequent and intensified rel ...... ee consecutive AML-BFM trials.
@en
Consequent and intensified rel ...... ee consecutive AML-BFM trials.
@nl
prefLabel
Consequent and intensified rel ...... ee consecutive AML-BFM trials.
@en
Consequent and intensified rel ...... ee consecutive AML-BFM trials.
@nl
P2093
P2860
P356
P1433
P1476
Consequent and intensified rel ...... ee consecutive AML-BFM trials.
@en
P2093
C von Neuhoff
D Reinhardt
G Fleischhack
G J L Kaspers
M Zimmermann
U Creutzig
P2860
P2888
P304
P356
10.1038/LEU.2010.127
P577
2010-06-10T00:00:00Z
P5875
P6179
1026370498